Gain Therapeutics
GANX
33 hedge funds and large institutions have $8.24M invested in Gain Therapeutics in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 2 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
176% more call options, than puts
Call options by funds: $47K | Put options by funds: $17K
32% more funds holding
Funds holding: 25 → 33 (+8)
7% more capital invested
Capital invested by funds: $7.68M → $8.24M (+$560K)
2.64% more ownership
Funds ownership: 7.48% → 10.11% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jones Financial Companies
Des Peres,
Missouri
|
+$731K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$279K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$231K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$38K |
| 2 |
GAM
Gotham Asset Management
New York
|
-$9.25K |
| 3 |
Citigroup
New York
|
-$4.32K |
| 4 |
BlackRock
New York
|
-$3.67K |
GANX Hedge Fund Activity: Q1 2025 in Review
33 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2025, worth a combined $8.24M — up 7.3% from $7.68M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GANX positions and 2 closed out — a net gain of 8 holders — while 12 added to existing stakes and 2 trimmed.
The largest buyer was Jones Financial Companies, adding an estimated $731K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $38K sold.
- 33 institutional investors held Gain Therapeutics (GANX) as of Q1 2025, up from 25 in Q4 2024.
- Funds reported $8.24M of Gain Therapeutics stock for Q1 2025, up 7.3% quarter-over-quarter.
- 10 funds opened new Gain Therapeutics positions in Q1 2025 and 2 closed out, a net change of +8 holders.
- The largest Gain Therapeutics buyer in Q1 2025 was Jones Financial Companies, an estimated $731K added.
- The largest Gain Therapeutics seller in Q1 2025 was Royal Bank of Canada, an estimated $38K sold.
Based on aggregated 13F filings for Q1 2025.